Sudden death and hypertrophic cardiomyopathy: A review

Canadian Journal of Cardiology

Volumn 21, Issue 5, 2005, Pages 441-448

  Ly, Hung Q ^a   Greiss, Isabelle ^a   Talajic, Mario ^a   Guerra, Peter G ^a   Macle, Laurent ^a   Thibault, Bernard ^a   Dubuc, Marc ^a   Roy, Denis ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Hypertrophic cardiomyopathy; Implantable cardioverter defibrillator; Risk stratification; Sudden cardiac death

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST;

AGE; BLOOD PRESSURE; CLINICAL TRIAL; DEFIBRILLATION; DEFIBRILLATOR; DISEASE PREDISPOSITION; DRUG RESPONSE; ECHOCARDIOGRAPHY; FAMILY HISTORY; GENE MUTATION; GENETIC DISORDER; HEART ARREST; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PRIMARY PREVENTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SARCOMERE; SECONDARY PREVENTION; SUDDEN DEATH; SURVIVAL RATE; SYNCOPE; TREATMENT FAILURE; TREATMENT OUTCOME;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; GENOTYPE; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 19644386525     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J 1958;20:1-8.
2. Tam JW, Shaikh N, Sutherland E. Echocardiographic assessment of patients with hypertrophic and restrictive cardiomyopathy: Imaging and echocardiography. Curr Opin Cardiol 2002;17:470-7.
3. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: Morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995;26:1699-708.
4. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-85.
5. Braunwald E, Seidman CE, Sigwart U. Contemporary evaluation and management of hypertrophic cardiomyopathy. Circulation 2002;106:1312-6.
6. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92:785-9.
7. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol 1993;72:970-2.
8. Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 1989;320:749-55.
9. Kofflard MJ, Waldstein DJ, Vos J, Ten Cate FJ. Prognosis in hypertrophic cardiomyopathy observed in a large clinic population. Am J Cardiol 1993;72:939-43.
10. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients. J Am Coll Cardiol 2000;36:2212-8.
11. Maron BJ. Hypertrophic cardiomyopathy: A systematic review. JAMA 2002;287:1308-20.
12. Kofflard MJ, Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: Clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 2003;41:987-93.
13. Maron BJ, Oliviotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a non-referral-based patient population. Circulation 2000;102:858-64.
14. McKenna WJ, Franklin RC, Nihoyannopoulos P, Robinson KC, Deanfield JE. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988;11:147-53.
15. McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy: Assessment of patients at risk. Circulation 1989;80:1489-92.
16. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999;281:650-5.
17. Firoozi S, Sharma S, Hamid S, McKenna WJ. Sudden death in young athletes: HCM or ARVC? Cardiovasc Drugs Ther 2002;16:11-7.
18. Maron BJ. Sudden death in young athletes. N Engl J Med 2003;349:1064-75.
19. Freedman RA. Use of implantable pacemakers and implantable defibrillators in hypertrophic cardiomyopathy. Curr Opin Cardiol 2001;16:58-65.
20. McKenna WJ, Firoozi S, Sharma S. Arrhythmias and sudden death in hypertrophic cardiomyopathy. Card Electrophysiol Rev 2002;6:26-31.
21. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027-35.
22. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;22:796-804.
23. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: Management, risk stratification, and prevention of sudden death. Heart 2002;87:169-76.
24. Yetman AT, McCrindle BW, MacDonald C, Freedom RM, Gow R. Myocardial bridging in children with hypertrophic cardiomyopathy - a risk for sudden death. N Engl J Med 1998;339:1201-9.
25. Möhlenkamp S, Hort W, Ge J, Erbel R. Update on myocardial bridging. Circulation 2002;106:2616-22.
26. Nicod P, Polikar R, Peterson KL. Hypertrophic cardiomyopathy and sudden death. N Engl J Med 1988;318:1255-7.
27. Ruppel R, Schluter CA, Boczor S, et al. Ventricular tachycardia during follow-up in patients resuscitated from ventricular fibrillation: Experience from stored electrograms of implantable cardioverter-defibrillators. J Am Coll Cardiol 1998;32:1724-30.
28. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 1989;13:1283-8.
29. Primo J, Geelen P, Brugada J, et al. Hypertrophic cardiomyopathy: Role of the implantable cardioverter-defibrillator. J Am Coll Cardiol 1998;31:1081-5.
30. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-73.
31. Silka MJ, Kron J, Dunnigan A, et al. Sudden death and the use of implantable cardioverter-defibrillators in pediatric patients. Circulation 1993;87:800-7.
32. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001;357:420-4.
33. Nishimura RA, Holmes DR. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004;350:1320-7.
34. McKenna W, Deanfield J, Faruqui A, England D, Oakley C, Goodwin J. Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981;47:532-8.
35. Maron BJ, McKenna WJ, Danielson GK, et al; Task Force on Clinical Expert Consensus Documents; American College of Cardiology; Committee for Practice Guidelines; European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687-713.
36. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997;96:2987-91.
37. Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:2044-51.
38. Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: A prospective study. Am J Cardiol 1981;48:252-7.
39. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42:873-9.
40. Wynne J, Braunwald E. The cardiomyopathies and myocarditides. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine, 6th edn. Philadelphia: WB Saunders Company, 2001:1751-803.
41. Maron BJ. Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Cardiol Rev 2002;10:173-81.
42. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348;295-303.
43. Maron BJ. Hypertrophic cardiomyopathy. Curr Probl Cardiol 1993;18:639-704.
44. Smolders W, Rademakers F, Conraads V, Snoeck J. Apical hypertrophic cardiomyopathy. Acta Cardiol 1993;48:369-83.
45. Gosselin G, Pasternac A, Lesperance J, Bijak A, Waters DD. Apical hypertrophic cardiomyopathy: Clinical and angiographic characteristics of the first Canadian series. Can J Cardiol 1988;4:258-61.
46. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-85.
47. Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, Cecchi F. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003;41:315-21.
48. Jarcho JA, McKenna W, Pare JA, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14ql. N Engl J Med 1989;321:1372-8.
49. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995;332:1058-64.
50. Watkins H. Sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:422-4.
51. Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: A comprehensive outpatient perspective. J Am Coll Cardiol 2002;39:2042-8.
52. Fananapazir L, Epstein SE. Prevalence of hypertrophic cardiomyopathy and limitations of screening methods. Circulation 1995;92:700-4.
53. Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992;86:730-40.
54. Saeed M, Homoud M, Wang PJ, Estes NA III, Link MS. Role of electrophysiologic testing in risk stratification for sudden cardiac death. J Invasive Cardiol 2001;13:758-62.
55. Zhu DW, Sun H, Hill R, Roberts R. The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 1998;21:299-302.
56. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: Clinical spectrum and treatment. Circulation 1995;92:1680-92.
57. Maron BJ, Bonow RO, Cannon RO III, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: Interrelations of clinical manifestations, pathophysiology and therapy. N Engl J Med 1987;316:780-9.
58. Jayatilleke I, Dodan A, Ingles J, et al. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am J Cardiol 2004;93:1192-4.
59. Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: Improved survival following high-dose beta-adrenoreceptor antagonist treatment. J Am Coll Cardiol 1999;34:1813-22.
60. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985;53:412-6.
61. Fananapazir L, Leon MB, Bonow RO, et al. Sudden death during amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol 1991;67:169-74.
62. Fananapazir L, Epstein SE. Value of electrophysiologic studies in hypertrophic cardiomyopathy treated with amiodarone. Am J Cardiol 1991;67:175-82.
63. Mercereau D, Kubac G, Klinke WP. Failure of amiodarone to prevent ventricular fibrillation (sudden death) in hypertrophic cardiomyopathy. Can J Cardiol 1989;5:77-80.
64. Prasad K, Frenneaux MP. Hypertrophic cardiomyopathy: Is there a role for amiodarone? Heart 1998;79:317-8.
65. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: Assessment in an unselected non-referral based patient population. Heart 1998;79:331-6.
66. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:1596-601.
67. Chatrath R, Porter CB, Ackerman MJ. Role of transvenous implantable cardioverter-defibrillators in preventing sudden cardiac death in children, adolescents, and young adults. Mayo Clin Proc 2002;77:226-31.
68. Frenneaux MP. Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy. Heart 2004;90:570-5.
69. Maron BJ, Isner JM, McKenna WJ. 26th Bethesda conference: Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: Hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol 1994;24:880-5.
70. Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004;109:2807-16.